Frankfurt
20.11.24
08:24 Uhr
0,058 Euro
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| Mi | AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm | 210 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / November 20, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 11.11. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - September 2024 | 604 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / November 11, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - September... ► Artikel lesen | |
| 30.10. | AlzeCure Pharma: AlzeCure Presents New Anti-Inflammatory Data with NeuroRestore ACD856 at the Alzheimer's Conference CTAD | 389 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / October 30, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 28.10. | AlzeCure Pharma: AlzeCure Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis | 177 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / October 28, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases... ► Artikel lesen | |
| 24.10. | AlzeCure Pharma: AlzeCure to Present at the International Partnering Conference Bioscience 2024 on November 7 | 217 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / October 24, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 17.10. | AlzeCure Pharma's CEO Martin Jönsson to present at Redeye's Neurology Day | 211 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / October 17, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 10.10. | AlzeCure Pharma Broadcasts Live Event About the Phase II Candidate ACD440 Against Neuropathic Pain | 219 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / October 10, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 02.10. | AlzeCure's abstract on ACD856's effects to be presented at Alzheimer's conference | 5 | PharmaTimes | ||
| 01.10. | AlzeCure Pharma: AlzeCure's Abstract on ACD856's Anti-inflammatory Effects to be Presented at a Leading Alzheimer's Conference | 214 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / October 1, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 26.08. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - June 2024 | 379 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / August 26, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - June... ► Artikel lesen | |
| 13.08. | AlzeCure Pharma: New Scientific Article on NeuroRestore ACD856 and its Improved Cognition and Disease Modification of Alzheimer's Disease | 575 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / August 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 07.08. | AlzeCure Pharma: New Results from AlzeCure's Pain Project TrkA-NAM Presented at the Pain Conference IASP 2024 | 248 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / August 07, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 13.06. | AlzeCure Pharma: New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain | 337 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / June 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 28.05. | Nasdaq Stockholm AB: New last day of trading in paid subscription shares (BTA) of AlzeCure Pharma AB (publ) | 201 | GlobeNewswire | At the request of AlzeCure Pharma AB (publ), the last trading day in AlzeCure
Pharma AB (publ)'s paid subscription units will be changed from May 30, 2024 to
May 31, 2024.
Short name: ALZCUR BTA... ► Artikel lesen | |
| 15.05. | AlzeCure Pharma: Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Elected as a New Board Member | 545 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / May 15, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB, a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's... ► Artikel lesen | |
| 14.05. | Communiqué from the Annual General Meeting of AlzeCure Pharma on 14 May 2024 | 632 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) Today, 14 May 2024, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below is a... ► Artikel lesen | |
| 13.05. | AlzeCure Pharma: AlzeCure Reports Anti-Inflammatory Effects with NeuroRestore ACD856 with Relevance to Alzheimer's Leading to New Patent Application | 264 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / May 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 30.04. | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of AlzeCure Pharma AB | 366 | GlobeNewswire | With effect from May 02, 2024, the subscription rights in AlzeCure Pharma AB
will be traded on First North Growth Market. Trading will continue up until and
including May 14, 2024.
Instrument: Subscription... ► Artikel lesen | |
| 25.04. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - March 2024 | 764 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / April 25, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - March... ► Artikel lesen | |
| 25.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 25.04.2024 | 292 | Xetra Newsboard | Das Instrument AB2 NL0011540547 ABN AMRO BANK DR/EO1 EQUITY wird cum Kapitalmassnahme gehandelt am 25.04.2024 und ex Kapitalmassnahme am 26.04.2024 The instrument AB2 NL0011540547 ABN AMRO BANK DR/EO1... ► Artikel lesen |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 430,05 | +0,44 % | VERTEX - Wie kurz sind die Beine politischer Börsen? | ||
| VIATRIS | 12,365 | -0,80 % | Viatris Inc. Q3 Profit Decreases, But Beats Estimates | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS) released a profit for third quarter that decreased from the same period last year but beat the Street estimates.The company's earnings came in at $94.8... ► Artikel lesen | |
| OPKO HEALTH | 1,508 | +0,27 % | Opko Health CEO Phillip Frost kauft Aktien im Wert von 161.980 US-Dollar | ||
| ALTIMMUNE | 7,538 | -1,26 % | Altimmune, Inc: Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024 | ||
| JAGUAR HEALTH | 0,965 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Family Company Napo Therapeutics Named "Best Pharmaceuticals Innovator of the Year - Europe" | Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar's novel oral plant-based prescription drug, in Europe for orphan and/or rare diseases SAN... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,240 | +5,80 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update | - Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 - - Data from the Phase 2a Trial of SLS009 in Relapsed/Refractory... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 7,558 | -3,40 % | Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development | ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 3,450 | 0,00 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies | Encinitas, California--(Newsfile Corp. - November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided... ► Artikel lesen | |
| LIPOCINE | 4,730 | 0,00 % | Lipocine Inc. - 8-K, Current Report | ||
| PHOTOCURE | 4,515 | +5,49 % | Photocure ASA: Results for the third quarter of 2024 | OSLO, Norway, Nov. 13, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 120.1 million in the third quarter of 2024 (Q3 2023: NOK 107.3 million)... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 3,721 | -0,72 % | Aclaris upgraded to overweight by Cantor on in-licensing deal | ||
| SOLID BIOSCIENCES | 4,965 | 0,00 % | Solid Biosciences Inc.: Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates | - Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 25,600 | 0,00 % | Eurobio Scientific: Results For The 1st Half Of 2024 | RESULTS FOR THE 1ST HALF OF 2024 Revenues up 12% on a like-for-like basis (24% overall)Stable adjusted EBITDA1 and operating profitNet financial debt down slightly to €1.6m, with cash of €86.6mProposed... ► Artikel lesen | |
| MEDICURE | 0,580 | 0,00 % | Medicure, Inc.: Medicure to Present Financial Results on November 26, 2024 Call at 8:30 AM ET for Quarter Ended September 30, 2024 and Announces Resignation of Board Member | WINNIPEG, MB / ACCESSWIRE / November 18, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| BAYER | 19,390 | -0,79 % | Bayer AG Aktie: Der Druck wächst | Die Bayer AG Aktie durchlebt turbulente Zeiten an der Börse. Nach einer erneuten Gewinnwarnung fiel der Kurs auf den tiefsten Stand seit zwei Jahrzehnten, wobei allein im laufenden Jahr ein Wertverlust... ► Artikel lesen |
Das Unternehmen ALZECURE PHARMA AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,058 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.
